The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc.’s Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.

The federal indictment alleged the two executives engaged in “false and misleading representations and material omissions” regarding the development of experimental monoclonal antibody leronlimab.

The treatment, developed by British drugmaker GlaxoSmithKline, is the first non-pill option against HIV, and studies have shown it even outperforms the efficacy of oral pills.

World AIDS Day on December 1 is an opportunity for people worldwide to unite in the fight against HIV and AIDS. It’s also time to take stock, be honest, and realize that we still have work to do to protect our communities.

The number of people in Europe with undiagnosed HIV has risen as testing rates fell during the COVID-19 pandemic, threatening a global goal of ending the disease by 2030, a report said.

For years digital health platforms have been integral in helping navigate viral outbreaks such as HIV, COVID-19, and monkeypox. Ramin Bastani, CEO of Healthvana – a platform that delivers test results and records (the company just surpassed 50 million records delivered) to get patients on the right track to receive treatment – talks about how such digital health solutions are improving the response to disease outbreaks.

Yesterday the U.S. health regulator issued an emergency use authorization to Roche’s test for the detection of DNA from monkeypox virus in swab specimens collected from people suspected of the virus infection.

Why your “commitment to listening” is not enough for communities facing public health emergencies.

CytoDyn withdrew its pending Biologics License Application for the monoclonal antibody in HIV Friday, citing concerns involving the contract research organization managing its trials.  

Gilead Sciences Inc. on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.